Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox may have issued materially misleading business information to the investing public.

On August 10, 2016, Seeking Alpha published an article revealing that Nymox management has consistently and repeatedly misled shareholders about its prospects in a material way while dumping stock at inflated prices without making timely disclosures to the Securities and Exchange Commission. On this news, shares of Nymox fell sharply during intraday trading on August 10, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Nymox investors. If you purchased shares of Nymox on or before August 10, 2016, please visit the firm's website at for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at or

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on

Copyright Business Wire 2010